Welcome to our dedicated page for Organogenesis Holdings SEC filings (Ticker: ORGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Organogenesis Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Organogenesis Holdings's regulatory disclosures and financial reporting.
Organogenesis Holdings Inc. (ORGO) insider activity: A director and 10% owner reported Form 4 transactions. An affiliated trust purchased 251,001 shares of Class A common stock on 05/14/2025 at a weighted-average price of $3.0878 and 107,494 shares on 05/15/2025 at a weighted-average price of $2.9862. The same trust sold 4,156 shares on 06/09/2025 at a weighted-average price of $3.5003 and 18,620 shares on 06/10/2025 at a weighted-average price of $3.5583.
Following the reported transactions, holdings included 335,719 shares indirectly by the Glenn Nussdorf 10 Year Follow On Trust and 3,065,591 shares held directly. The filing notes that the sales on 06/09/2025 and 06/10/2025 were matchable with a 05/15/2025 purchase under Section 16(b), and the reporting person paid the issuer $13,285.24, comprising $12,971.78 in profit plus $313.46 in interest.
Organogenesis Holdings, Inc. filed a Form 8-K reporting a material event that includes a press release dated September 25, 2025 and referenced data from Phase 3 randomized controlled trials (ReNu) dated the same day. The filing indicates the press release and trial data are provided as part of the 8-K's disclosures and that the interactive cover page data are embedded in the Inline XBRL document. The filing is signed by Lori Freedman, Chief Administrative and Legal Officer.
The filing text supplied here contains no actual trial results, financial figures, forward-looking statements, or additional narrative about the ReNu data, and therefore does not disclose outcomes, metrics, or impacts on operations or finances.
Organogenesis Holdings, Inc. Schedule 13G shows First Light Asset Management, LLC and Mathew P. Arens report joint beneficial ownership of common stock. The Manager is reported to beneficially own 8,061,404 shares (representing 6.35% of the class) while Mr. Arens is reported to beneficially own 8,309,404 shares (6.55%), including 231,000 shares held directly with sole voting and dispositive power. The filing is made under Rule 13d-1(b) and includes a joint filing agreement.
Organogenesis Holdings Inc. reporting person Brian Grow, the company's Chief Commercial Officer, disclosed transactions on 08/11/2025 involving both stock-option exercise and share transactions. The filing shows the exercise of a stock option that resulted in 4,060 Class A common shares acquired at an exercise price of $2.47, and it states that 100% of the shares subject to the option are fully vested and exercisable.
The Form 4 also reports a transaction involving 2,173 Class A common shares at a reported price of $4.615. The filing lists beneficial ownership figures of 674,550 and 672,377 Class A common shares on the respective lines, indicating the reporting person continues to hold hundreds of thousands of shares following these transactions.
Organogenesis Holdings Inc. (ORGO) – Schedule 13D/A (Amendment 10) filed 06/24/2025
The filing updates beneficial ownership information for a long-standing reporting group comprised of company founders, related trusts and affiliated investment vehicles. No purchase or sale prices are disclosed in the excerpt; however, the cover page states that the amendment was triggered by an event on June 24 2025.
Key ownership positions disclosed
- Alan A. Ades: 22,319,836 shares (17.6% of Class A common), of which 11.2 million are held with sole voting/dispositive power and 11.1 million with shared power.
- Albert Erani: 17,920,498 shares (14.1%) – approximately 6.8 million sole and 11.1 million shared.
- Glenn H. Nussdorf: 11,912,841 shares (9.4%) – 11.0 million sole, 0.9 million shared.
- Dennis Erani: 10,043,701 shares (7.9%) – 1.3 million sole, 8.7 million shared.
- Organo PFG LLC: 8,279,490 shares (6.5%) – all sole voting/dispositive.
- Other entities & individuals: Organo Investors LLC (2.9 million / 2.2%), Alan Ades 2014 GRAT (3.1 million / 2.4%) and Starr Wisdom (20,000 / <0.1%).
Based on the amounts reported, the group collectively controls approximately 76.4 million Class A shares. Although total shares outstanding are not provided in the excerpt, each of the first four individuals continues to exceed the 5% reporting threshold, indicating significant insider alignment with shareholders. The amendment does not specify whether positions increased or decreased relative to the prior filing.
No financial performance metrics, transaction prices or strategic commentary accompany the ownership data, suggesting that the filing is largely administrative—updating share counts and voting arrangements among a pre-existing insider group.
Organogenesis Holdings Inc. (Nasdaq: ORGO) filed an 8-K covering the results of its 23 June 2025 Annual Meeting and a preferred-stock director election.
Board & Executive Matters
- Series A Convertible Preferred holders unanimously re-elected Garrett Lustig to the Board.
- All nine management-nominated directors were re-elected; the highest support was 72.4 million votes (95.8% of votes cast) for Gilberto Quintero, while the lowest was 68.9 million (93.9%) for Jon Giacomin.
- Say-on-Pay advisory resolution passed with 91.4% support (67.1 m for / 6.3 m against).
Capital Structure Proposal
- Shareholders approved—by 45.4 m for vs. 2.7 m against—the potential issuance of >20% of outstanding Class A shares upon conversion of Series A Preferred below Nasdaq “minimum price,” a step that could be deemed a change-of-control under Rules 5635(b)/(d).
Audit Matters
- RSM US LLP was ratified as independent auditor for FY 2025 with 96.4% support (103.6 m for / 3.9 m against).
Quorum: 107.5 million Class A votes were present (inclusive of 25.4 m as-converted preferred shares, subject to Nasdaq’s 19.99% cap).
The filing is largely routine governance disclosure; however, the preferred-stock conversion approval introduces potential future dilution that current shareholders should monitor.